ALRN Aileron Therapeutics Inc.

0.42
+0.01  (+1%)
Previous Close 0.41
Open 0.41
Price To Book 0.39
Market Cap 11,652,540
Shares 27,810,358
Volume 530,022
Short Ratio
Av. Daily Volume 494,931
Stock charts supplied by TradingView

NewsSee all news

  1. Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer's Palbociclib at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the

  2. Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer's IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today announced that an

  3. Aileron Therapeutics Announces Management Change

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced

  4. Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

    WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Noted that development to be discontinued - no pivotal trial.
ALRN-6924
Peripheral T-cell lymphoma (PTCL)
Phase 1/1b trial ongoing.
ALRN-6924 and Cytarabine (Ara-C)
Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)
Phase 2a preliminary data at ESMO 2019 noted not PRs; SD = 88%. Final data due 2Q 2020.
ALRN-6924 and IBRANCE (palbociclib)
Solid tumors
Phase 1 has been initiated.
ALRN-6924 and Paclitaxel
Breast cancer
Phase 1b/2 initiation announced October 16, 2019 with data due 2Q 2020.
ALRN-6924
Small Cell Lung Cancer (SCLC)

Latest News

  1. Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer's Palbociclib at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the

  2. Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer's IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today announced that an

  3. Aileron Therapeutics Announces Management Change

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced

  4. Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

    WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced